DescriptionProduct Availability: In Stock (delivery within 2-3 business days, no extra charge for drop-shipping).Ordering: To place an order via credit card or PO use Add to Cart button (creating an account is not required).Transfection Reagent for ASPC-1 Cells (Pancreatic Beta Cells, CRL-1682)A nanoparticle-based liposome formulationTransfection protocols provided for transfection of proteins, DNA, mRNA, siRNA, shRNA and microRNATransfection Enhancer reagent provided with the kitProduce higher level of recombinant protein expression with minimal disruption of normal cell functionGenerate physiologically relevant data you can trustEffective for plasmid DNA/siRNA co-transfectionEasy-to-use transfection protocol with reproducible resultsLow cytotoxicityDownload in vitro ASPC-1 transfection protocol: [PDF]Download ASPC-1 CRISPR/Cas9 transfection protocol: [PDF]Download PowerPoint presentation for ASPC-1 cells transfection kit: [PPT]Developed and manufactured by Altogen BiosystemsTransfection Efficiency:Reagent exhibits at least 70% transfection efficiency of siRNA delivery. Transfection efficiency was determined by qRT-PCR.Transfection Protocol and MSDS:Download Altogen Biosystems ASPC-1 Transfection Protocol: [PDF]Download MSDS: [PDF]ASPC-1 Cell Line:Pancreatic cancer is one of the most challenging cancers to diagnose, as there no specific and reliable screening tests on the market that can help detect the disease in early stages. According to the American Cancer Society, if caught in its early stages, the 5-year survival rate is 27%, but if cancer metastasizes then this number goes down to 11%. The AsPC-1 cell line comprising pancreatic beta cells and is an invaluable tool for pancreatic cancer research as well as commonly employed for studying human infections related to the pancreas. The AsPC-1 cell line was reestablished via nude mouse xenografts initiated with cells from the ascites of a 62-year-old Caucasian woman with metastatic pancreatic adenocarcinoma. The reestablished epithelial cells retained their original morphology. This tumor represents a new model for human pancreatic cancer. AsPC-1 cells are used in studies seeking possible treatments for pancreatic cancer, which has a five-year survival rate of less than one percent. For examples, research has shown that the plant alkaloid sanguinarine induced apoptosis of AsPC-1 cells. In another study, immunoprecipitation and ELISA using human pancreatic cancer cells revealed the presence of high levels of DcR3 protein in AsPC-1 cells. Reducing endogenous DcR3 levels increases FasL-induced apoptosis of human pancreatic cancer cells. Another intriguing study indicated that deuterium oxide (D2O), also called heavy water, induced apoptosis of AsPC-1, and is considered a possible future treatment against AsPC-1.Data:Figure 1. Cyclophilin B silencing efficiency was determined by qRT-PCR in the AsPC-1 cells transfected by Cyclophilin B siRNA or non-silencing siRNA control following the recommended transfection protocol. Cyclophilin mRNA expression levels were measured 48 hours post-transfection. 18S rRNA levels were used to normalize the Cyclophilin B data. Values are normalized to untreated sample. Data are presented as means ± SD (n=3).Figure 2. Protein expression of Cyclophilin B in AsPC-1 cells. DNA plasmid expressing Cyclophilin B or siRNA targeting Cyclophilin B were transfected into AsPC-1 cells following Altogen Biosystems transfection protocol. At 72 hours post-transfection the cells were analyzed by Western Blot for protein expression levels (normalized by total protein, 10 µg of total protein loaded per each well). Untreated cells used as a negative control.Selected in vivo transfection product citations (ALTOGEN® IN VIVO Transfection Kits used in the following publications):Nature. 2008 454(7203):523-7. Innate immunity induced by composition-dependent RIG-I …Saito et al [PDF]Am J Pathology. 2010 177(4):1870-80. Role of ocular complement factor H in a murine model … Lyzogubov et al [PDF]Nature Biotechnology. 2011 29(4):341-5. Delivery of siRNA to the mouse brain by … Alvarez-Erviti et al [PDF]Cancer Research. 2011 71(15):5144-53. Inhibition of miR-193a expression by… Iliopoulos et al [PDF]RNA. 2010 16(11):2108-19. RNase L releases a small RNA from HCV RNA that refolds … Malathi et al [PDF]Diabetologia. 2012 55(7):2069-79. The p47phox- and NADPH oxidase organiser 1 … Youn et al [PDF]British Journal of Cancer. 2012 107(3):516-26. TIGAR induces p53-mediated cell-cycle … Madan et al [PDF]Hypertension. 2014 63(2):353-61. Tissue transglutaminase contributes to … Liu et al [PDF]Circulation Research. 2010 15;107(8). Kruppel-like factor-4 transcriptionally regulates … Cowan et al [PDF]Hypertension. 2012 59(1):158-66. Role of uncoupled endothelial nitric oxide synthase … Gao et al [PDF]Jounal of Biological Chemistry. 2012 287(4):2907. Chaperoning of mutant p53 protein … Gogna et al [PDF]PLoS Pathogens. 2012 8(8) Uridine composition of the poly-U/UC tract of HCV RNA … Schnell et al [PDF] Request a Quote forAsPC-1 Transfection ReagentAltogen Biosystems: Altogen Biosystems provides preoptimized transfection products for life science research applications. Transfection protocols are optimized for individual cancer cell lines. Altogen Biosystems developed two types of in vivo delivery kits for animal research: Tissue-targeted reagents (delivery to liver, pancreas, and kidney tissues), and broad range in vivo delivery reagents (PEG-Liposome, Nanoparticle-based, Lipid-based, and Polymer-based kits). Advanced formulation of reagents and optimized transfection protocols provide efficient intracellular delivery of proteins, DNA, RNA, and any other negatively charged molecules in vitro and in vivo. Read more about transfection technology at Altogen’s Transfection Resource.Altogen Labs Research Services:Altogen Labs provides GLP-compliant contract research studies for pre-clinical research, IND applications, and drug development. Biology CRO services include: Xenograft models (30+), development of stable cell lines, ELISA assay development, cell-based and tissue targeted RNAi studies, safety pharm/tox assays, and other studies (visit AltogenLabs.com). Volume Options:0.5 ml (Catalog #1709)1.5 ml (Catalog #1710)1.5 ml CRISPR (Catalog #2109)8.0 ml (Catalog #7023)
Altogen Biosystems全国代理部分产品列表：
|
货号
|
产品
|
规格
|
价格（美元）
|
|
5030
|
|
|
|
|
1703
|
A204 Transfection Reagent (Rhabdomyosarcoma)
|
0.5ml
|
170
|
|
1704
|
A204 Transfection Reagent (Rhabdomyosarcoma)
|
1.5ml
|
348
窗体顶端
窗体底端
|
|
2101
|
A204 Transfection Reagent (Rhabdomyosarcoma)
|
1.5ml CRISPR
|
548
窗体顶端
窗体底端
|
|
7018
|
A204 Transfection Reagent (Rhabdomyosarcoma)
|
8.0ml
|
1044
窗体顶端
窗体底端
|
|
1167
|
A375 Cells Transfection Reagent (CRL-1619)
|
0.5ml
|
195
|
|
1168
|
A375 Cells Transfection Reagent (CRL-1620)
|
1.5ml
|
427
|
|
2102
|
A375 Cells Transfection Reagent (CRL-1621)
|
1.5ml CRISPR
|
627
|
|
1169
|
A375 Cells Transfection Reagent (CRL-1622)
|
8.0ml
|
1281
|
|
5030
|
Nanoparticle In Vivo Transfection Reagent
|
0.5 ml - 10 injections
|
445
|
|
5010
|
LIPID In Vivo Transfection Reagent
|
0.5 ml - 10 injections
|
405
|
|
5040
|
PEG-Liposome In Vivo Transfection Reagent
|
0.5 ml - 10 injections
|
465
|
|
5020
|
POLYMER In Vivo Transfection Reagent
|
0.5 ml - 10 injections
|
425
|
|
5050
|
Pancreas In Vivo Transfection Kit
|
0.5 ml - 10 injections
|
495
|
|
5060
|
Liver In Vivo Transfection Kit
|
0.5 ml - 10 injections
|
495
|
|
5070
|
Kidney In Vivo Transfection Kit
|
0.5 ml - 10 injections
|
495
|
|
1721
|
BMS2 Transfection Reagent (Bone Marrow Cells)
|
0.5 ml
|
231
|
|
6345
|
C6 Transfection Reagent (Glioma Cells, CCL-107)
|
0.5 ml
|
199
|
|
6803
|
DLD-1 Transfection Reagent (Colon Cancer, CCL-221)
|
0.5 ml
|
201
|
|
1775
|
HUH-7 Transfection Reagent (Liver Cancer Cells)
|
0.5 ml
|
179
|
